相关临床试验
256
18 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1821
进行中（未招募）
5
1.9%
已完成
147
57.4%
Enrolling By Invitation
1
0.4%
尚未招募
12
4.7%
招募中
44
17.2%
暂停
1
0.4%
终止
13
5.1%
Unknown
30
11.7%
撤回
3
1.2%
暂无批准数据
- HDT Bio has established HDT Bio Canada Inc. and partnered with McGill University and The Neuro to advance HDT-401 into Phase 1 clinical evaluation for glioblastoma. - HDT-401 combines Riboxxim, a TLR3/RIG-I agonist, with the LION™ lipid delivery platform to convert the glioblastoma microenvironment from immune-suppressed to immune-engaged via local administration. - Encouraging compassionate use results informed the Phase 1 trial design, and a pre-CTA meeting with Health Canada has been completed with constructive feedback received. - Glioblastoma carries a five-year survival rate below 5%, and no approved immunotherapy has demonstrated a survival benefit to date, underscoring the urgent unmet need.
- A University of Alberta study analyzing 971 TikTok videos found anti-sunscreen content, though only 6% of total posts, garners disproportionately high audience engagement compared to pro-sunscreen messaging. - Researchers identified that only 6% of sunscreen-related TikTok content mentions cancer risk reduction, with the majority instead focusing on beauty and anti-aging benefits. - A separate 2023 study in Cancer Epidemiology, Biomarkers & Prevention found the "sunscreen paradox" — where sunscreen users may experience increased skin cancer risk due to a false sense of security leading to prolonged UV exposure, not due to sunscreen itself. - Experts recommend dermatologists and brands adopt shorter, clearer messaging on social media that directly addresses sunscreen's role in skin cancer prevention while acknowledging patient concerns.
- A three-year-old Surrey boy has been diagnosed with Hereditary Spastic Paraplegia Type 4 (HSP), a rare progressive neurodegenerative disease with no known cure. - McGill University's Dr. Ziv Gan-Or has committed to developing a personalized gene therapy, with total costs estimated between $6 and $8 million. - The family has raised $2.4 million toward the initial $2.7 million needed to kickstart therapy development, including a 120-km walk from Vancouver to Victoria. - The Gills are traveling to Parliament Hill in Ottawa from June 8–10 to advocate for faster government support and access to life-saving gene therapies for children with rare diseases.
- ValiRx, an AIM-listed life sciences company, raised £1.155 million through equity financing at a 17% discount to fund early-stage cancer therapeutics and women's health programs. - The funding will support in-licensing activities, intellectual property expansion, preclinical development, and growth of the company's animal health division. - Key near-term milestones include patent grants for the Cytolytix programme and validation of ValiRx Animal Health's primary indication, with readouts expected between July and November. - The company is pursuing a capital-efficient model focused on licensing, partnerships, and non-dilutive funding rather than traditional high-cost biotech development approaches.
- The Phase II BEAVER trial evaluated the combination of binimetinib (MEK1/2 inhibitor) and encorafenib (BRAF kinase inhibitor) in patients with advanced solid tumors harboring non-V600E BRAF mutations. - Results showed encouraging clinical activity with significant tumor regression and prolonged disease stabilization in a subset of patients, demonstrating meaningful inhibition of signaling cascades across diverse non-V600E mutation classes. - The dual-inhibitor regimen achieved manageable toxicity profiles with adverse events including skin toxicity, gastrointestinal symptoms, and laboratory abnormalities within expected parameters. - This research represents a critical milestone in personalized oncology by expanding treatment options for patients with non-V600E BRAF mutations, who historically had limited therapeutic alternatives.
- Agora Open Science Trust has nominated M4K2009 as the lead development candidate for treating Diffuse Intrinsic Pontine Glioma (DIPG), a rare and devastating pediatric brain cancer. - The ALK2 inhibitor demonstrated excellent potency, selectivity, brain penetration, and tolerability in preclinical models after evaluation of hundreds of compounds through multi-year collaborative research. - This milestone represents a significant advancement in open science drug discovery, with the program now moving into IND-enabling studies toward clinical trials. - The development was supported by multiple international partners and Canada's Strategic Innovation Fund through Conscience's Developing Medicines through Open Science program.
- McGill University researchers discovered that lithium, a widely used bipolar disorder medication, can prevent HIV-infected cells from reactivating in laboratory studies. - The study challenges previous assumptions by demonstrating that lithium's HIV suppression effects persist even when autophagy pathways are disrupted, suggesting alternative mechanisms are involved. - While promising for HIV functional cure research, lithium has not been tested in humans as an HIV treatment and carries significant side effects that prevent immediate clinical application.
- Epitopea's CryptoMap platform identified 589 non-redundant tumor antigens in cutaneous melanoma and NSCLC, with only 1% derived from mutated sequences. - The platform discovered that 37% of identified tumor antigens were Cryptigens, which are immunogenic, shared among tumor samples, and could contribute to immune checkpoint blockade responses. - This research challenges the conventional focus on mutated tumor antigens and validates unmutated sequences as actionable targets for cancer immunotherapy. - The findings distinguish Epitopea's approach from other immunotherapy companies and support the development of accessible off-the-shelf RNA-based immunotherapies.
- Clinical trials of VIA Disc NP, a minimally invasive treatment using donor nucleus pulposus tissue, demonstrated significant reduction in chronic back pain from 7.1 to 3.8 on a 10-point scale over 12 months. - The procedure, developed by VIVEX Biologics, involves injecting morselized donor disc tissue into degenerated spinal discs, allowing patients to return home the same day and resume normal activities within 24 hours. - Researchers reported substantial functional improvements, with the percentage of patients in "severe" or "crippled" disability categories dropping from 82% to 18%, suggesting potential to delay or prevent more invasive surgical interventions.
• Recent analysis of lecanemab (Leqembi) clinical trial data reveals a 31% difference in drug effectiveness between male and female Alzheimer's patients, with men showing a 43% slowing of cognitive decline compared to just 12% in women. • Researchers from McGill University conducted 10,000 simulated trials based on Phase 3 CLARITY AD data, finding the gender disparity occurred randomly in only 12 simulations, suggesting the difference is statistically meaningful. • The findings have significant implications for clinical practice as two-thirds of Alzheimer's patients are female, highlighting the urgent need for sex-specific considerations in both drug development and treatment decisions.
